OUD Revision Focus Areas

Goal: Narrow down focus areas further (e.g., into 2-3 actions for a broad range of systems, or lots of actions for 2-4 audiences). What is the biggest problem that if solved would have the largest impact?

Examples:

- Establishing defined pathways to low-barrier initiation of MOUD across different healthcare settings and payment landscapes to support them
- Widespread adoption of trauma-informed care and harm reduction principles into clinical care
- BH integration models across various settings (critical access hospitals, rural clinics, FQHCs, stand-alone primary care clinics, pre-hospital services, etc) and experience levels with treating OUD

Previous Audiences

- Patients and Families
- Clinicians
- Programs and Facilities
- Health Plans
- Washington State Agencies: HCA, DOH, DOC, Division Behavioral Health Recovery, DSHS, LNI
- Employers
- Health Services Academic Training Programs and Residencies
- Washington State Legislature?

Original Focus Areas		New Focus Areas
Access to Evidence-Based Treatment	 Medication treatment – buprenorphine, methadone, and naltrexone (e.g., increase geographic reach, increase number of providers) Reduction in stigma associated with treatment 	 Low barrier pathways to MAT (buprenorphine formulations) Trauma-informed care and harm reduction principles Payment models/reimbursement supporting low-barrier initiation
Referral Information	 Providers and patients know where to access care. Accessible inventory of buprenorphine and methadone prescribers Referral infrastructure that supports patients and providers 	

Integrated Behavioral and Physical Health to Support Whole-Person Care	 Treatment of co-morbid conditions including multiple substance use, mental illness, physical health in line with BHI report and recommendations 	 Payment models and reimbursement supporting BH integration Models of BHI for providers with various experience in identifying and treating
		OUD

Potential Speakers/Guests:

- Syringe Exchange Programs
- Correctional Facilities
- Patient Advocacy Groups?